Biotech News Alert: GenSpera (OTCQB:GNSZ) to Present at Rodman & Renshaw
16th Annual Global Investment Conference
CEO to Present
Significance of Announced Clinical Trial Results for Lead Drug G-202 Treating Hepatocellular
Carcinoma (HCC) Patients to Wall Street Audience
SAN
ANTONIO, Texas, August 14, 2014 – (Investorideas.com Biotech Newswire) GenSpera,
Inc. (OTCQB:GNSZ), a leader in
developing prodrug therapeutics for the treatment of cancer, announces it will
be presenting at the Rodman & Renshaw 16th Annual Global Investment
Conference. The conference will be held September 8-10, 2014 at the New York
Palace Hotel in New York.
The
conference is attended by public companies, institutional investors, sophisticated
private investors and industry executives.
GenSpera
will be presenting at 12:05 pm Tuesday, September 9th. The Company will discuss
the significance of the recently announced HCC clinical trial update for G-202,
its lead drug candidate, as well as provide a corporate overview. The company
has released interim results from the Phase Ib and ongoing Phase II study in
hepatocellular carcinoma (HCC) patients who had previously progressed on, or
who were intolerant of sorafenib (Nexavar®, a drug co-developed and co-marketed
by Bayer and Onyx Pharmaceuticals, an Amgen subsidiary). Impressively, 80% of patients treated with
G-202 had stable disease (no tumor growth) at two months and 50% of patients
exhibited stable disease at 4 months on study. In addition, imaging analysis
demonstrated impressive blockade of tumor blood flow in the single patient
evaluated by this method to date.
Hepatocellular
carcinoma (HCC) is currently the sixth most common malignancy in the world and
the third leading cause of cancer-related mortality worldwide.
Craig
Dionne, PhD, GenSpera's CEO said of the pending conference,” I am excited to
share the recent data and results for G-202 and its efficacy and safety
analyses on patients to date. G-202 has potential to treat multiple cancers
including prostate cancer and glioblastoma but our primary focus is currently hepatocellular
carcinoma (HCC). The liver cancer data we recently presented at APPLE and other
scientific conferences was overwhelmingly embraced by our peers; now this
conference creates an opportunity to explain the significance and the promise
it holds to the investment community.”
About
the conference: http://www.rodm.com/
Read this release
in full at http://www.investorideas.com/CO/GNSZ/news/2014/08141.asp
About GenSpera
GenSpera’s
technology platform combines a powerful, plant-derived cytotoxin (thapsigargin)
with a prodrug delivery system that provides for the targeted release of drug
candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin
results in cell death irrespective of the rate of cell division, which may
provide an effective approach to kill both fast- and slow-growing cancers.
GenSpera’s lead drug candidate, G-202, is activated by the enzyme PSMA, which
is found at high levels in the vasculature of liver and glioblastoma cancers
and in the vasculature of almost all other solid tumors. G-202 is therefore
expected to have potential efficacy in a wide variety of tumor types.
G-202
Phase II clinical trials are underway in both hepatocellular carcinoma and
glioblastoma patients.
For
more information, please visit the company’s website: www.genspera.com or follow us on Twitter @GenSperaNews.
Company
presentations are available at: http://www.genspera.com/
Watch
the Corporate Video:
Cautionary Statement Regarding Forward
Looking Information
This news
release may contain forward-looking statements. Investors are cautioned that
statements in this press release regarding potential applications of GenSpera’s
technologies constitute forward-looking statements that involve risks and
uncertainties, including, without limitation, risks inherent in the development
and commercialization of potential products, uncertainty of clinical trial
results or regulatory approvals or clearances, need for future capital,
dependence upon collaborators and maintenance of our intellectual property
rights. Actual results may differ materially from the results anticipated in
these forward-looking statements. Additional information on potential factors
that could affect our results and other risks and uncertainties will be
detailed from time to time in GenSpera’s periodic reports filed with the
Securities and Exchange Commission.
Company:
Craig Dionne, PhD,
CEO
GenSpera, Inc. (210) 479-8112
Investors:
Steve
Gersten
Capital
Markets Group
Steve@CapMarketsGroup.com
+1-813-926-8920
Media:
Dawn
Van Zant
(800)
665 0411
Disclaimer/Disclosure:
Investorideas.com newswire is a third party publisher of news and research as
well as creates original content as a news source. Original content created by
investorideas is protected by copyright laws other than syndication rights.
Investorideas is a news source on Google news and Linkedintoday plus hundreds
of syndication partners. Our site does not make recommendations for purchases
or sale of stocks or products. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. All investment
involves risk and possible loss of investment. This site is currently
compensated by featured companies, news submissions, content marketing and
online advertising. Contact each company directly for press release questions.
Disclosure is posted on each release if required but otherwise the news was not
compensated for and is published for the sole interest of our readers. More
disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera (GNSZ) has engaged Investor
Ideas for PR and news publication effective June 18, 2014 (compensation of five
thousand per month and average of eleven thousand five hundred 144 shares per
month)
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global
investors must adhere to regulations of each country.
Become an
Investorideas.com Member and access our 14 online stock directories 24/7 –biotech,
mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/
No comments:
Post a Comment